icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Software company GitLab (GTLB.US) is considering a sale, sending shares up more than 10% in premarket trading.

Market VisionWednesday, Jul 17, 2024 4:50 am ET
1min read

Software developer GitLab (GTLB.US) is considering a sale, with Alphabet (GOOGL.US), its investor, valued at about $8bn.

GitLab shares jumped more than 10% in premarket trading on Wednesday, and were up 11.25% at $56.36 at the time of writing.

GitLab is currently working with investment bankers on a sale process, which has attracted interest from rivals including cloud monitoring company Datadog (DDOG.US), which is valued at about $44bn.

Any deal would still need several weeks to close and is not yet certain. Alphabet owns 22.2% of GitLab’s voting shares through its venture capital arm.

Technology deals are accelerating as artificial intelligence and cloud computing drive companies to expand their product offerings. Alphabet is in advanced talks to buy cybersecurity startup Wiz for about $23bn, after considering a deal for marketing software company HubSpot (HUBS.US).

Dealogic data shows technology companies accounted for the largest share of global M&A activity in the first half of 2024, up more than 42% year-on-year to $327bn.

GitLab’s platform allows development, operations and security teams to design and manage software using a single tool. It has more than 30mn registered users and more than half of the Fortune 100 use it.

GitLab’s shares have fallen 16% this year, underperforming the S&P 500 software index’s 3% rise, as investors worry about cuts to its customers’ spending. The company reported a 33% year-on-year increase in revenue to $169m in the latest quarter, and its first positive cash flow, but admitted its product pricing was under pressure due to competition with Microsoft after it acquired rival GitHub for $7.5bn in 2018.

Sid Sijbrandij, chief executive and co-founder, controls 45.51% of GitLab’s voting shares through dual-class structure. He said on the company’s earnings call last month that he would receive his second round of chemotherapy for bone marrow cancer, which he had also received last year, and that he was working to fully recover and continue to fulfil his duties.

Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App